Telomir Pharmaceuticals, Inc. (TELO) Stock Forecast
TELO analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $4.00 average of analyst targets
- Upside to target
- +281.0% from the latest close
- Next earnings
- November 9, 2026
- 52-week range
- $0.92 – $1.66
TELO analyst ratings
1 analystsNumber of analysts at each rating.
TELO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TELO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.03 | −$0.03 | −$0.03 | −$0.03 | 0.0% | 1 |
| Current fiscal year (FY2026) | −$0.11 | −$0.11 | −$0.11 | −$0.33 | +66.7% | 1 |
| Next fiscal year (FY2027) | −$0.17 | −$0.17 | −$0.17 | −$0.11 | −54.5% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TELO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (FY2026) | $0 | $0 | $0 | — | 1 |
| Next fiscal year (FY2027) | $0 | $0 | $0 | 0.0% | 1 |
TELO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TELO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | $0.00 | −$0.03 | — | 0 up · 0 down |
| Current fiscal year (FY2026) | $0.00 | $0.00 | $0.00 | $0.00 | −$0.11 | — | 0 up · 0 down |
| Next fiscal year (FY2027) | $0.00 | $0.00 | $0.00 | $0.00 | −$0.17 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TELO earnings surprises
Reported EPS vs the consensus estimate for the last 10 quarters; TELO beat in 2 of 4.
What analysts expect from TELO
1 analysts cover Telomir Pharmaceuticals; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.00, 281.0% above the latest close of $1.05. Analysts expect earnings of −$0.11 per share for FY2026, +66.7% from a year earlier. For FY2027 the average estimate is −$0.17 per share. Telomir Pharmaceuticals beat the EPS estimate in 2 of the last 4 quarters.
Related: TELO income statement, TELO key metrics, TELO chart. See the TELO stock overview for the latest quote and news.
TELO forecast FAQ
What is Telomir Pharmaceuticals's price target?
The average analyst price target for Telomir Pharmaceuticals is $4.00, 281.0% above the latest close of $1.05.
Is Telomir Pharmaceuticals a buy, hold or sell?
Of 1 analysts covering Telomir Pharmaceuticals, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Telomir Pharmaceuticals's EPS forecast?
Analysts forecast −$0.11 per share for FY2026 (range −$0.11 to −$0.11); for FY2027 the estimate is −$0.17.
When does Telomir Pharmaceuticals report earnings?
Telomir Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
Does Telomir Pharmaceuticals usually beat earnings estimates?
Telomir Pharmaceuticals reported EPS at or above the analyst estimate in 2 of the last 4 quarters.